

Communiqué from extraordinary general meeting in ScandiDos AB

An extraordinary general meeting was held on 2 May 2019 in ScandiDos AB (publ) ("ScandiDos" or the "Company") in Advokatfirman Lindahl's facilities on Vaksalagatan 10 in Uppsala whereby the shareholders primarily resolved on the following matters.

Decision regarding adoption of new articles of association

The extraordinary general meeting resolved to amend the articles of association regarding the limits of the Company's share capital and the number of shares (§ 4 and § 5) in accordance with the following.

Previous wording

§ 4 The share capital shall be not less than SEK 500,000 and not more than SEK 2,000,000.

§ 5 The number of shares shall be not less than 15,000,000 and not more than 60,000,000.

New wording

§ 4 The share capital shall be not less than SEK 1,300,000 and not more than SEK 5,200,000.

§ 5 The number of shares shall be not less than 25,000,000 and not more than 100,000,000.

Resolution regarding approval of the board of directors' decision to issue new shares with pre-emption rights for existing shareholders

The extraordinary general meeting resolved to approve the board of directors' resolution on 2 April 2019 to issue shares with pre-emption rights for existing shareholders on the main terms set out below.

The board of directors' resolution entails that the Company's share capital may increase with not more than SEK 690,981.15 by an issue of not more than 13,819,623 new shares on the terms and conditions set out below.

The right to subscribe for new shares shall belong to the persons who on the record date for the new issue of shares are recorded as shareholders of the Company, whereby two (2) existing shares shall entitle to one (1) subscription right and one (1) subscription right shall entitle to subscribe for one (1) new share.

In the event that all new shares are not subscribed for with pre-emption rights, the board of directors shall, within the limit of the maximum number of shares to be issued, resolve on allocation of shares that are not subscribed for with pre-emption rights. Such allocation shall firstly be made to subscribers that have used subscription rights in the issue in relation to the number of subscription rights that each subscriber has used to subscribe for new shares and secondly to other subscribers in relation to subscribed amount, and if this cannot be made, through drawing of lots.

A new share that has been issued by virtue of a warrant entitles to participation in the new issue of shares, provided that such subscription has been executed no later than Thursday 25 April 2019.

The record date for participation in the new issue of shares shall be Wednesday 8 May 2019.

The new shares are issued at a subscription price of SEK 2.50 per share. Thus, the Company will receive SEK 34,549,057.50 upon full subscription (before transaction costs).

Subscription with pre-emption rights shall be made by cash payment during the period from 13 May 2019 to 27 May 2019. The board of directors shall have the right to extend the subscription and payment period.

Subscription without pre-emption rights shall be made on a subscription list during the period from 13 May 2019 to 27 May 2019. Payment shall be made in full by cash payment no later than five business days after information on allotment has been sent. The board of directors shall have the right to extend the subscription and payment period.

The new shares entitle to dividends for the first time on the first record date for dividends that takes place after the issue of new shares has been registered with the Swedish Companies Registration Office and the new shares have been recorded in the share register kept by Euroclear Sweden AB.

The resolution on the new issue of shares is subject to approval by the general meeting and requires that the Company's articles of association are amended.

The managing director, or any other person appointed by the board of directors, shall have the right to take those smaller measures that may be required in order to register the resolution with the Swedish Companies Registration Office and Euroclear Sweden AB.

The resolutions from the extraordinary general meeting were adopted unanimously.

Uppsala 2 May 2019
ScandiDos AB (publ)

Contact

Görgen Nilsson, CEO
Telephone: +46 18 472 30 30
E-mail: gorgen.nilsson@scandidos.com
www.scandidos.com

About ScandiDos AB

With its Delta⁴ Phantom, now updated as the Delta⁴ Phantom+, ScandiDos AB has assumed a leading role in advanced dosimetry and quality assurance of modern cancer radiation therapy. The Delta⁴ Discover, which is now validated for clinical use by Varian, allows clinics to provide radiation dosage verification during ongoing treatment of patients, thereby increasing the quality of the treatment and patient safety. The measurement system and advanced calculation programs from ScandiDos provide physicians, physicists and patients with validation that the advanced cancer radiation treatment is delivered precisely in the quantity and manner as planned.

Headquartered in Uppsala, Sweden, ScandiDos was founded in 2002 and has grown to include offices in Madison, Wis., Beijing and Paris. With its global footprint, ScandiDos has installed dosimetry and QA solutions in 45 countries, and its systems can be found in leading cancer centers worldwide. The Company has partnership agreements with Varian and Elekta, which include ScandiDos products in their sales systems.

Since April 2014, ScandiDos has been listed on NASDAQ First North Stockholm with the ticker symbol SDOS. Erik Penser Bank, www.penser.se, is Certified Adviser to the Company.